J&J also lobbied on issues regarding personalized medicine, a growing field that could boost sales of its diagnostic tests and biologic drugs, and on incentives for developing sorely needed new antibiotics.Besides Congress and the White House, the company lobbied the Commerce Department and the U.S. Trade Representative's office, according to a quarterly disclosure report filed on July 20 with the House clerk's office. Julie Cohen, a former staff director of the U.S. Special Committee on Aging and a former aide to Sen. Herb Kohl, D-Wis., was among those registered to lobby for the company. A federal law enacted in 1995 requires lobbyists to disclose activities that could influence members of the executive and legislative branches.
WASHINGTON (AP) â¿¿ Health products giant Johnson & Johnson spent $1.3 million in the second quarter lobbying on legislation concerning its medicines and consumer health products, many of which have been the subject of repeated recalls over the past two years. That amount was up slightly from the $1.2 million the New Brunswick, N.J., company spent a year earlier, but down from the $1.7 million it spent in the first quarter. The maker of Tylenol, Motrin and hip replacements â¿¿ products among the many J&J has recalled around the world â¿¿ lobbied on issues relating to recalls of nonprescription medicines made by its McNeil Consumer Healthcare unit and ingredients in cough and cold medicines that can be abused or used to make the illegal drug methamphetamine. Since September 2009, J&J has announced an astounding series of more than two dozen recalls of prescription and nonprescription drugs and medical devices. Reasons range from nauseating odors and shards of metal or glass in liquid medicines to the wrong level of active ingredient in some over-the-counter medicines and faulty hip replacements that cause severe pain and require replacement. The company lobbied on the America Invents Act, the first significant overhaul of patent law since 1952. The legislation, signed into law by President Obama on Sept. 16, is meant to stimulate job creation by streamlining the patent process, reducing costly legal battles and addressing a backlog of about 1.2 million pending patent approvals. J&J also lobbied on issues related to Food and Drug Administration fees for reviewing and deciding whether to approve new medicines and medical devices, as well as on ensuring the quality of medication ingredients, on rebates paid for drugs purchased through the Medicare program, and for repeal of an excise tax on medical devices. The company, which makes many popular baby and skin care products, lobbied on regulation of cosmetic products. It also lobbied on tax reform and on a free-trade agreement with Korea.